IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment
International Immunopharmacology · 2023-10 · 123 · 110757
DOI: 10.1016/j.intimp.2023.110757 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023-10. Verfasst von Meiying Song und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China. Hauptthemen laut MEDLINE: Autoimmune Diseases, Neoplasms. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 183 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, Natural Science Foundation of Qingdao Municipality.
Abstract (Originalsprache)
Interleukin 17A (IL-17A) is a major member of the IL-17 cytokine family and is produced mainly by T helper 17 (Th17) cells. Other cells such as CD8+ T cells, γδ T cells, natural killer T cells and innate lymphoid-like cells can also produce IL-17A. In healthy individuals, IL-17A has a host-protective capacity, but excessive elevation of IL-17A is associated with the development of autoimmune diseases and cancer. Monoclonal antibodies (mAbs) targeting IL-17A (e.g., ixekizumab and secukinumab) or IL-17A receptor (IL-17RA) (e.g., brodalumab) would be investigated as potential treatments for these diseases. Currently, the application of IL-17A-targeted drugs in autoimmune diseases will provide new ideas for the treatment of tumors, and its combined application with immune checkpoint inhibitors has become a research hotspot. This article reviews the mechanism of action of IL-17A and the application of anti-IL-17A antibodies, focusing on the research progress on the mechanism of action and therapeutic blockade of IL-17A in various tumors such as colorectal cancer (CRC), lung cancer, gastric cancer and breast cancer. Moreover, we also include the results of therapeutic blockade in the field of cancer as well as recent advances in the regulation of IL-17A signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.
- Department of Special Medicine, School of Basic Medical College, Qingdao University, Qingdao, Shandong 266071, PR China.
- School of Emergency Medicine, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.
- Department of Liver Transplantation, School of Clinical Medicine, Qingdao University, Qingdao, Shandong 266071, PR China.
- Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China. Electronic address: zhangbei124@aliyun.com.
Förderung
- Natural Science Foundation of Shandong Province
- Natural Science Foundation of Qingdao Municipality
Zitieren
APA
Song, M., Liang, J., Wang, L., Li, W., Jiang, S., Xu, S., Tang, L., Du, Q., Liu, G., Meng, H., Zhai, D., Shi, S., Yang, Y., Zhang, L., & Zhang, B. (2023). IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment. International Immunopharmacology, 123, 110757. https://doi.org/10.1016/j.intimp.2023.110757
Vancouver
Song M, Liang J, Wang L, Li W, Jiang S, Xu S, et al. IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment. International Immunopharmacology. 2023;123:110757. doi:10.1016/j.intimp.2023.110757
BibTeX
@article{Song2023,
author = {Song, Meiying and Liang, Jie and Wang, Luoyang and Li, Wei and Jiang, Suli and Xu, Shuo and Tang, Lei and Du, Qiaochu and Liu, Guixian and Meng, Haining and Zhai, Dongchang and Shi, Shangheng and Yang, Yanyan and Zhang, Li and Zhang, Bei},
title = {IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment},
journal = {International Immunopharmacology},
year = {2023},
volume = {123},
pages = {110757},
doi = {10.1016/j.intimp.2023.110757}
}
EUVIMED